TransCode begins patient dosing in Cohort 4 of phase 1 trial with TTX-MC138 to treat metastatic cancer: Boston Monday, March 31, 2025, 18:00 Hrs [IST] TransCode Therapeutics, Inc.

Modern medicine is a marvel, with previously unimaginable cures and treatments now widely available. Think of advanced ...

Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

Ainnova has hired an ophthalmologist, who is assisting in drafting the requirements for the clinical trial protocol that the Company's Contract Research Organization (CRO), Fortrea, has requested.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration ...

Q4 2024 Management View CEO Punit Dhillon highlighted significant progress with the clinical development of nimacimab, including the completion of patient enrollment for the CBeyond Phase IIa trial ...

Routine use of urodynamic testing for overactive bladder (OAB) did not improve patient-reported outcomes when combined with ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...